ReviewFrontiers in immunology2025
Advanced omics approaches in liver transplant settings: current applications and future prospectives.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST), as advanced omics technologies, have addressed critical challenges in liver transplantation (LT), the most effective treatment for end-stage liver disease. This review aims to summarize the applications and future directions of scRNA-seq and ST in the context of LT. We highlight their role in uncovering immune cell heterogeneity and related injury mechanisms post-transplantation. From a clinician's perspective, we also outline potential future developments in the application of advanced omics in LT. Specifically, we focus on key immune cells involved in LT, with an emphasis on post-transplant immune responses and ischemia-reperfusion injury (IRI), as revealed by scRNA-seq and ST. Furthermore, we underscore the importance of multi-omics approaches and dynamic omics analyses in clinical LT research. With ongoing technological advancements, the integration of cutting-edge omics technologies and artificial intelligence (AI) holds great promise for advancing precision medicine in LT. Emphasis should be placed on the value of single-cell and spatial omics technologies in improving precision therapy and clinical management for LT patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.